![Bin Dong](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bin Dong
Direktor/Vorstandsmitglied bei Beijing Xiangxin Biotechnology Co., Ltd.
Profil
Bin Dong has worked as a Director at Beijing Xiangxin Biotechnology Co., Ltd.
since 2019.
Aktive Positionen von Bin Dong
Unternehmen | Position | Beginn |
---|---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
![]() Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Direktor/Vorstandsmitglied | 13.11.2019 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
![]() Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Health Technology |